A phase II trial of oral UFT plus cisplatin (CDDP) in patients with non-small cell lung cancer (NSCLC)

Lung Cancer

Volumn 31, Issue 2-3, 2001, Pages 285-293

  Saito, Junichi ^a   Nakai, Yushi ^a   Saijo, Yasuo ^b   Nukiwa, Toshihiro ^b   Koinumaru, Sadahiro ^c   Matsuura, Yoshifumi ^d   Aso, Noboru ^e   Yamane, Yoshio ^f   Tsukamoto, Tomei ^g   Sayama, Tsuneo ^h   Nakabayashi, Takehito ⁱ  

^a Sendai Kosei Hospital   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c Miyagi Cancer Center   (Japan)

^d Ota Nishinouchi Hospital   (Japan)

^e Miyagi Prefectural Semine Hospital   (Japan)

^f Iwaki Kyoritsu General Hospital   (Japan)

^g Yamagata Prefectural Central Hospital   (Japan)

^h Tohoku Central Hospital   (Japan)

ⁱ HOKKAIDO CANCER CENTER   (Japan)

Author keywords

Cisplation; NSCLC; Oral UFT

Indexed keywords

ALANINE AMINOTRANSFERASE; CISPLATIN; TEGAFUR; UFT; URACIL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG CAPSULE; DRUG EFFICACY; DRUG INFUSION; DRUG RESPONSE; FEMALE; HEMATURIA; HUMAN; HYPERBILIRUBINEMIA; LARGE CELL CARCINOMA; LEUKOPENIA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA;

ADMINISTRATION, ORAL; ADULT; AGED; ANEMIA; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; SURVIVAL ANALYSIS; TEGAFUR; THROMBOCYTOPENIA; TREATMENT OUTCOME; URACIL;

EID: 0035139614     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(00)00183-5     Document Type: Article

References (19)

1. Alternating sequential cisplatin (CDDP) and 5-fluorouracil (FU) in continuous infusion (CI) for advanced bronchogenic carcinoma
2. One-sample multiple testing procedure for phase II clinical trials
3. Pilot trial of a combination comprising of consecutive oral administration of UFT, and two-divided administration of CDDP in non small cell lung cancer
4. Sequential continuous infusion (CI) cisplatin (CDDP) and CI 5-fluorouracil (FU) in unresectable non-small cell lung cancer (NSCLca)
5. Comparison of 5-fluorouracil parmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2′-tetrahydrofuryl)-5-fluorouracil
6. A comparison of 5-fluorouracil concentration of 5-fluorouracil drip infusion versus orally UFT in plasma of same patients
7. A study of infusional cisplatin and infusional fluorouracil for locally advanced or metastatic non-small-cell lung cancer: a Mid-Atlantic Oncology Program Study
8. A phase II trial of oral tegafur and uracil plus cicplatin in patients with inoperable non-small cell lung cancer
9. Clinical trial of cisplatin and 5-FU infusion as initial treatment for advanced squamous cell cacinoma of the head and neck
10. Pilot study of UFT combined with 5-consecutive days cisplatin in non-small cell lung cancer
11. In vivo comparative therapeutic study of optimal administration of 5-fluorouracil and cisplatin using a newly established HST-1 human squamous-carcinoma cell line
12. A phase II trial of UFT plus cisplatin in patients with advanced non-small cell lung cancer
13. Toxicity and response criteria of the Eastern Cooperative Oneology Group
14. Chemotherapy with 5-fluorouracil (5FU) and cisplatin or 5-FU, cisplatin, and vinblastine for advanced non-small cell lung cancer
15. A study of oral etoposide, infusional cisplatin and infusional 5-fluorouracil for locally advanced or metastatic non-small cell lung cancer
16. Confidence intervals for reporting results of clinical trials
17. Cisplatin bolus and 5-FU infusion chemotherapy for non-small cell lung cancer
18. Experimental study of the effect of combined treatment of UFT with CDDP on human solid tumor-xenografts in nude mice